In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …

Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …

Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark
of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study …

The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular
processes and is frequently altered in cancer, contributing to tumor growth and survival …

Background Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell …

Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the
tumor, which in most cases results from its dependence on an oncogene and/or loss of a …

Abstract Phosphoinositide 3-kinase (PI3K) signaling regulates cellular proliferation, survival
and metabolism, and its aberrant activation is one of the most frequent oncogenic events …

Abstract Oestrogen receptor-positive (ER+) breast cancer is a major cause of cancer death
in women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …